Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs.
Bald
Dirk
D
Department of Molecular Cell Biology, Faculty of Earth and Life Sciences, VU University Amsterdam, Amsterdam, The Netherlands. dirk.bald@falw.vu.nl
Koul
Anil
A
D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D000900:Anti-Bacterial Agents; D055808:Drug Discovery; D004734:Energy Metabolism / Q000187:drug effects*; D006801:Humans; D008954:Models, Biological; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism*; D010084:Oxidation-Reduction
D000900:Anti-Bacterial Agents; D000255:Adenosine Triphosphate